RxDoctor Payments Data

Anthonia Umelogu

Psychiatric/Mental Health · Detroit, MINPI 1518485911

Payments from drug & device makers

$1,036in general payments, 2019–2025

Across 36 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$286
  • E.r. Squibb & Sons, L.L.C.$277
  • Otsuka America Pharmaceutical, Inc.$126
  • Luye Pharma (USA) Ltd.$71
  • Johnson & Johnson$56
  • Indivior Inc.$53
  • plus $167 from 5 others

What the payments were for

  • Food & beverage$1,036100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 60th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$14,270
Medicare patients
34
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate68$170,328
Invega TrinzaPaliperidone Palmitate16$125,236
AristadaAripiprazole Lauroxil29$67,837
VraylarCariprazine Hcl22$31,978
Paliperidone ErPaliperidone129$27,927
TrintellixVortioxetine Hydrobromide43$21,091
Risperidone ErRisperidone Microspheres16$16,819
Fluphenazine Hcl47$9,100
Aripiprazole172$8,529
Haloperidol Decanoate141$6,579
Quetiapine Fumarate337$5,696
Haloperidol175$4,805
Benztropine Mesylate380$3,818
Divalproex Sodium ErDivalproex Sodium92$3,550
Desvenlafaxine Succinate ErDesvenlafaxine Succinate47$3,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$56$295,56484 claims
Alkermes, Inc.Aristada$286$67,83729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →